Rather than stopping entirely and risking the weight regain documented in the STEP 1 extension trial (Wilding et al., Diabetes Obes Metab, 2022), where participants regained two-thirds of lost weight within one year of stopping, a microdose may provide enough GLP-1 receptor activation to maintain the appetite set-point shift
Weight loss injections used before IVF usually belong to a group of medications called GLP-1 receptor agonists
There are no reports of significant hormonal disruption, no blood sugar effects, and no serious adverse events attributable to the peptide
Ann Pharmacother 49:351359 Jendle J, Grunberger G, Blevins T, Giorgino F, Hietpas RT, Botros FT (2016) Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program
You can pause or cancel anytime
Why it occurs: Your body may need time to adjust to new peptides, especially those targeting metabolism
